Naftopidil, a new adrenoceptor blocking agent with Ca(2+)-antagonistic properties: interaction with adrenoceptors.

Sponer, G; Borbe, H O; Müller-Beckmann, B; Freud, P; Jakob, B

Sponer, G; Borbe, H O; Müller-Beckmann, B; Freud, P; Jakob, B.

Affiliation

Sponer G; Pharmacological Laboratories, Boehringer Mannheim GmbH, Germany.

J Cardiovasc Pharmacol ; 20(6): 1006-13, 1992 Dec.

Article in En | MEDLINE | ID: mdl-1282583

Subject(s)

Adrenergic alpha-Antagonists/pharmacology; Calcium Channel Blockers/pharmacology; Naphthalenes/pharmacology; Piperazines/pharmacology; Receptors, Adrenergic/drug effects; Adrenergic alpha-Antagonists/metabolism; Adrenergic beta-Antagonists/pharmacology; Animals; Binding, Competitive/drug effects; Blood Pressure/drug effects; Calcium Channel Blockers/metabolism; Decerebrate State/physiopathology; In Vitro Techniques; Male; Muscle Relaxation/drug effects; Muscle, Smooth, Vascular/drug effects; Naphthalenes/metabolism; Norepinephrine/pharmacology; Piperazines/metabolism; Propranolol/pharmacology; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic/metabolism; Vasodilation/drug effects

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Calcium Channel Blockers / Receptors, Adrenergic / Adrenergic alpha-Antagonists / Naphthalenes Limits: Animals Language: En Journal: J Cardiovasc Pharmacol Year: 1992 Document type: Article Affiliation country: Germany Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links